透過您的圖書館登入
IP:3.238.87.31
  • 期刊

過敏性鼻炎患者接受免疫療法之生活品質

Quality of Life for Allergic Rhinitis Patients after Immunotherapy

摘要


The aim of this study was to measure quality of life outcomes following immunotherapeutic treatment of allergic rthinitis. A cross-sectional study design with three groups was conducted. Twenty nine patients with allergic rhinitis (group AR) and twenty six patients with allergic rhinitis who had undergone immunotherapy (group ARIT) were evaluated with the generic outcome measure (validated Chinese version of the Medical Outcome Study Short-form 36 item Health Survey, SF-36) and disease-specific outcome measure (Allergic Rhinitis Quality of Life Instrument, ARQOL). Thirty people without allergic rhinitis (group Normal) also completed the ARQOL. The SF-36 and ARQOL survey scores were compared with normative data and each other. Group AR reported significant impacts (all p<0.05) in six out of eight SF-36 domains, the two insignificant domains being physical functioning and bodily pain. The only statistically significant difference in the eight SF-36 domains between the group ARIT and Taiwan norms was the general health domain (p<0.05). In the three ARQOL dimensions, the Pearson correlations of test-retest reliability were all greater than 0.9. Group Normal was found to have higher total and ARQOL subscale scores (p<0.05) than the other two groups, and group ARIT was also found to have significantly higher total and ARQOL subscale scores (p<0.05) than group AR, with the exception of medical resource utilization. There was no correlation between the SF-36 and ARQOL in group AR, but in group ARIT, the correlation between the six SF-36 domains and symptoms and activity restrictions in the three ARQOL dimensions were moderate to strong. In general, allergic rhinitis has great impact on generic QOL but generic QOL approaches the same level after immunotherapy. Although immunotherapy improves disease-specific QOL of allergic rhinitis patients, there still exist differences between patients with immunotherapy and normal persons. The high test-retest reliability of the ARQOL suggests that it is a stable instrument. Using the two different instrument is an objective method for assessing quality of life in patients with allergic rhinitis.

並列摘要


The aim of this study was to measure quality of life outcomes following immunotherapeutic treatment of allergic rthinitis. A cross-sectional study design with three groups was conducted. Twenty nine patients with allergic rhinitis (group AR) and twenty six patients with allergic rhinitis who had undergone immunotherapy (group ARIT) were evaluated with the generic outcome measure (validated Chinese version of the Medical Outcome Study Short-form 36 item Health Survey, SF-36) and disease-specific outcome measure (Allergic Rhinitis Quality of Life Instrument, ARQOL). Thirty people without allergic rhinitis (group Normal) also completed the ARQOL. The SF-36 and ARQOL survey scores were compared with normative data and each other. Group AR reported significant impacts (all p<0.05) in six out of eight SF-36 domains, the two insignificant domains being physical functioning and bodily pain. The only statistically significant difference in the eight SF-36 domains between the group ARIT and Taiwan norms was the general health domain (p<0.05). In the three ARQOL dimensions, the Pearson correlations of test-retest reliability were all greater than 0.9. Group Normal was found to have higher total and ARQOL subscale scores (p<0.05) than the other two groups, and group ARIT was also found to have significantly higher total and ARQOL subscale scores (p<0.05) than group AR, with the exception of medical resource utilization. There was no correlation between the SF-36 and ARQOL in group AR, but in group ARIT, the correlation between the six SF-36 domains and symptoms and activity restrictions in the three ARQOL dimensions were moderate to strong. In general, allergic rhinitis has great impact on generic QOL but generic QOL approaches the same level after immunotherapy. Although immunotherapy improves disease-specific QOL of allergic rhinitis patients, there still exist differences between patients with immunotherapy and normal persons. The high test-retest reliability of the ARQOL suggests that it is a stable instrument. Using the two different instrument is an objective method for assessing quality of life in patients with allergic rhinitis.

被引用紀錄


黃浚銘(2007)。結合BPN、AHP與CBR方法建構於智慧型肝病醫療診斷模式〔碩士論文,國立臺北科技大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0006-1608200717581100
留啟祐(2008)。整合資料探勘方法應用於肝病輔助診斷〔碩士論文,國立臺北科技大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0006-1108200821124700
龍愛玲(2011)。癌症病患之泌尿道症狀影響因素及泌尿道症狀與生活品質之關係〔碩士論文,臺北醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0007-2707201113460600
詹靜惠(2011)。過敏性鼻炎兒童醫療遵從行為及其相關因素之研究〔碩士論文,國立臺灣師範大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0021-1610201315221394
柯宜君(2011)。結合FCA與CBR方法應用於第二型糖尿病併發症診斷模式建立〔碩士論文,國立臺北科技大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0006-1407201112151200

延伸閱讀